Curcumin II for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Curcumin II may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed curcumin II in detail.
, Inhibitory Effect of
Curcuma xanthorrhiza
Extract Against SARS‐CoV‐2 D614G Virus‐Like Particle (VLP): Implications for COVID‐19 Therapy Development, The Scientific World Journal, doi:10.1155/tswj/8681808
Curcuma xanthorrhiza , a commonly used Indonesian medicinal plant, has been widely utilized in traditional remedies, yet its antiviral potential against SARS‐CoV‐2 remains poorly defined. The current study was aimed at investigating the effect of C. xanthorrhiza ethanol extract on inhibiting viral entry through in silico and in vitro studies. The active compounds of C. xanthorrhiza were characterized using liquid chromatography–high‐resolution mass spectrometry (LC‐HRMS). The identified compounds were screened according to the Lipinski, Ghose, Veber, and Egan rules, and their antiviral activity was predicted using the PASS server. Molecular docking and dynamic simulations were employed to determine binding affinity and stability between the selected compounds and the SARS‐CoV‐2 Spike D614G protein. The virus‐like particle (VLP) of SARS‐CoV‐2 G614D was produced in HEK‐293T cells via cotransfection of plasmids encoding spike‐EGFP, membrane, and envelope proteins, and its morphology was verified by transmission electron microscopy (TEM). The IC 50 value of C. xanthorrhiza extract on 16HBE14o‐ cells was analyzed using the WST‐1 method. 16HBE14o‐ cells were exposed to VLP and treated with C. xanthorrhiza at 2.5, 5, 10, 40, and 125 μ g/mL for 24 and 48 h. The EGFP intensity of VLP‐internalized cells was assessed through fluorescent microscopy. Curcumin, curcumin II, piperine, (+)‐ar‐turmerone, and peruvinine showed the strongest binding affinities (−7.5 to −6.2 kcal/mol), while curcumin, curcumin II, and (+)‐ar‐turmerone exhibited the most stable binding interactions. TEM confirmed successful VLP formation with a mean diameter of 52.94 ± 27.32 nm, and the IC 50 of the extract was 125 μ g/mL. Furthermore, C. xanthorrhiza extract at 2.5 μ g/mL significantly reduced VLP internalization after 24 h. These findings highlight C. xanthorrhiza as a promising natural candidate for SARS‐CoV‐2 inhibition, supported by consistent computational and experimental evidence.